Document:

Converted by EDGARwiz

BINDING LETTER OF INTENT

This Binding Letter of Intent dated on February 25, 2009  (the “Agreement”) outlines the general terms and conditions by which Michael Friedman/Commerce Online Technologies, with a principal address of 801 South Olive Ave., #113, West Palm Beach, FL 33401,  (the “Buyer”) and Seraph Security, Inc. (SRHS), (the “Seller”) (Buyer and Seller collectively the “Parties”), intend to facilitate a merger, acquisition, or other combinational transaction with a public company, traded under symbol “ SRHS ” (the “Vehicle”). The closing date of this agreement shall be on or before April 25th, 2009.  

THIS AGREEMENT IS NOT EFFECTIVE UNTIL RECEIPT OF FULLY EXECUTED DOCUMENTS ARE DELIVERED TO EACH PARTY

WHEREAS, the Buyer wishes to obtain a controlling interest in the Vehicle from the        

                       Seller;

NOW THEREFORE, the Seller and the Buyer hereby agree:

1.

Seller shall provide any and all corporate documentation as reasonably available to Seller, prior to, or at closing of the proposed transaction.

2.

Buyer shall honor $371,347.00 debt from Fishgate LLC and E-Benefits direct, Inc., making his rights non-dillutive and secured by stock. Buyer or appointed parties thereof may at any time purchase debt notes and a pre-determined price from note holders.

3.

In consideration for 10 million shares of common stock of the Company, Buyer shall include all assets and intellectual property of e-commerce solutions, proprietary software applications, all reseller agreements and client base, and waive salary for first year for control block of equity.

4.

Buyer and Seller agree on outstanding bills to be paid, including transfer agent, DTC, and pink sheets.com.

5.

Resignation of any and all Officers and Directors of SRHS shall occur after payment in full of the Promissory Note or as agreed to by parties.  Appointment of Mr. Friedman          as a Director, and   President, as well as further appointed members of the board, shall occur con-current with resignations of present officers of SRHS.

BUYER:

SELLER:

            

             B Michael Friedman:

             Member SRHS: 

 Leonard Gotshalk

/s/ B. Michael Friedman

/s/Leonard Gotshalk

___

By: B. Michael Friedman

By: /s/Leonard Gotshalk

___

Date: February 25, 2009

Date: February 25, 2009VSUS TECHNOLOGIES INC (Form: 10KSB, Received: 05/22/2006 17:21:04)

   

  

EBENEFITS, INCORPORATED

(A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED INCOME STATEMENT

YEAR ENDED DECEMBER 31, 2008

(Unaudited)

						
	Revenue

	 

	$

	––

	 

	 

	 

	 

	 

	 

	 

	 

	Operating expenses:

	 

	 

	 

	 

	 

	Administrative expenses

	 

	 

	37,453

	 

	 

	Total operating expenses

	 

	 

	37,453

	 

	 

	 

	 

	 

	 

	 

	 

	Loss from operations

	 

	 

	(37,453

	)

	 

	 

	 

	 

	 

	 

	 

	Loss before income taxes

	 

	 

	(37,453

	)

	 

	 

	 

	 

	 

	 

	 

	Provision for income taxes

	 

	 

	––

	 

	 

	 

	 

	 

	 

	 

	 

	Net loss

	 

	$

	(37,453

	)

	 

	 

	 

	 

	 

	 

	 

	Basic and diluted loss per share

	 

	$

	(0.24

	)

	 

	 

	 

	 

	 

	 

	 

	Weighted average number of shares outstanding

	 

	 

	152,678VSUS TECHNOLOGIES INC (Form: 10KSB, Received: 05/22/2006 17:21:04)

   

  

EBENEFITS, INCORPORATED

(A DEVELOPMENT STAGE COMPANY)

CONSOLIDATED BALANCE SHEET

					
	 

	 

	December 31,

	 

	 

	 

	2008

	 

	 

	 

	(Unaudited)

	 

	ASSETS:

	 

	 

	 

	CURRENT ASSETS

	 

	 

	 

	Cash and cash equivalents

	 

	$

	5,407

	 

	 
	 
	 
	 
	 

	 

	 

	 

	5,407

	 

	Other assets

	 

	 

	92,364

	 

	 
	 
	 
	 
	 

	 

	 

	$

	97,771

	 

	 

	 

	 

	 

	 

	LIABILITIES AND STOCKHOLDERS' DEFICIENCY:

	 

	 

	 

	 

	CURRENT LIABILITIES

	 

	 

	 

	 

	Accounts Payable and  accrued expenses

	 

	 

	57,668

	 

	 

	 

	 

	 

	 

	LONG-TERM LIABILITIES

	 

	 

	 

	 

	Related Party

	 

	 

	66,517

	 

	Note Payable

	 
	 
	397,000

	 

	Total liabilities

	 

	 

	521,185

	 

	 

	 

	 

	 

	 

	STOCKHOLDERS' EQUITY

	 

	 

	 

	 

	 Common Stock 250,000,000 shares authorized and 152,678 shares issued and outstanding                             

Additional Paid in Capital

	 
	 

	152

     (152) 

	 

	Accumulated deficit

	 

	 

	(423,414

	)

	 

	 

	 

	(423,414

	)

	 

	 

	$

	97,771Exhibit 10.1

Exhibit 10.1

Mr. Wes Crews

March 31, 2009

Dear Wes,

On behalf of Health Grades, Inc., we are pleased to have you join our company as Chief Operating
Officer, effective April 20, 2009. Outlined below are the terms of your employment:

At-Will Employment: At-will employment means that you are not employed by Health Grades
for any fixed term. Just as you have the right to terminate your employment at Health Grades for
any reason; Health Grades has the right to terminate your employment relationship at any time, and
for any reason, in the sole discretion of Health Grades.

Base Compensation: $250,000 annual salary, payable bi-weekly as part of HealthGrades’
normal payroll cycle.

2009 Cash Bonus: $30,000, payable in two equal installments of $15,000 on September 30,
2009 and December 31, 2009, respectively.

2009 Incentive Compensation Potential: Paid out annually based on your individual Incentive
Compensation Plan (the “Plan”) as determined by the Compensation Committee of the Board of
Directors. In addition, please note that this Plan is typically revised annually. Any modifications
to the Plan are at the sole discretion of HealthGrades and the Compensation Committee of the Board
of Directors. The total incentive compensation for 2009 will be up to 40% of Base Compensation
based upon achievement of the Company’s 2009 total revenue budget.

Restricted Shares of Company Stock (Time Vesting Shares): You will receive 100,000
restricted shares. These shares will be awarded on May 1, 2009. Vesting will begin on the date of
the award as follows: 10% one year from date of award (equal to 10,000 shares), 20% two years from
date of award (equal to 20,000 shares with a resulting cumulative vested share balance of 30,000
shares), 30% three years from date of award (equal to 30,000 shares with a resulting cumulative
vested share balance of 60,000 shares) and 40% four years from date of award (equal to 40,000
shares with a resulting cumulative vested share balance of 100,000 shares). Additional restricted
share awards may be made in the future at the discretion of the Compensation Committee of the Board
of Directors.

Restricted Shares of Company Stock (Performance Based Shares): You will receive 100,000
restricted shares. These shares will be awarded upon approval of the Compensation Committee of the
Board of Directors and vesting will begin at that time. Vesting for Performance Based shares will
occur as follows:

Vesting Schedule

Performance vesting in 25% increments upon achievement of:

	 	•	 	Annual revenues of $60 million;

	 	•	 	Annual revenues of $80 million;

	 	•	 	Operating income of $18 million and 30% operating margin; and

	 	•	 	Operating income of $25 million and 30% operating margin.

Upon a change in control, the Performance Based grants will vest from the grant date:

	 	•	 	25% within six months of grant date;

	 	•	 	50% if more than six months, but less than one year of grant date;

	 	•	 	75% more than one year, but less than two years;

	 	•	 	100% more than two years from grant date; and

	 	•	 	100% if our stockholders receive $8.00 or more per share in
connection with the change in control transaction

 

 

 

Paid Time Off (PTO): You will receive 26 days of accrued Paid Time Off per year. Health
Grades observes and compensates full-time employees for seven (7) national holidays per year.

Severance: In the event you are terminated by HealthGrades for other than “cause”, you
will be paid three months base salary. In addition, you will be paid an additional month’s base
salary for each month that you have not accepted an offer of employment up to a maximum of three
additional month’s base salary. “Cause” shall mean a finding by the Board of Directors that you
(i) have engaged in disloyalty to Health Grades, including, without limitation, fraud,
embezzlement, theft, commission of a felony or proven dishonesty, (ii) have disclosed trade secrets
or confidential information of Health Grades to persons not entitled to receive such information,
(iii) have breached any written non-competition or non-solicitation agreement between the Grantee
and the Employer or (v) has engaged in such other behavior detrimental to the interests of Health
Grades as the Board of Directors determines.

Note: Severance payout will be in accordance with HealthGrades’ regularly scheduled payroll cycle
for the period of time the severance will run.

Other Employee Benefits: As a full-time employee, you will be eligible to participate in
all other employee benefits, including 401(k) program, as described in the Employee Handbook.

We look forward to working with you. If you should have any questions, please call me at (303)
716-6535.

John J. Quattrone

Chairman, Compensation Committee of the Health Grades, Inc. Board of Directors

	 	 	 	 	 
	Offer expires on April 2, 2009Exhibit 10.1

Exhibit 10.1

P.O. Box 4000, Route 206 & Province Line Road, Princeton, NJ 08543-4000

SENT BY OVERNIGHT COURIER

March 31, 2009                           

ABT Holding Company

c/o Athersys, Inc.

3201 Carnegie Avenue

Cleveland, Ohio 44115

Attention: President

	Re: 	 	Amendment to the Extended Collaboration and License Agreement between Athersys, Inc. and Bristol-Myers
Squibb Company effective January 1, 2006.

Dear Sir or Madam:

This letter agreement (this “Letter Amendment”), effective as of the date set forth above, by ABT Holding
Company (“Athersys”), formerly operating as “Athersys, Inc.” prior to a name change related to its 2007 reverse merger
with a wholly-owned subsidiary of a public shell company (subsequently renamed Athersys, Inc.), and Bristol-Myers
Squibb Company (“BMS”), is intended to set forth the Parties’ mutual understandings with respect to, and hereby
amends, that certain Extended Collaboration and License Agreement between the Parties effective January 1, 2006 (the
“Extended Agreement”), as set forth herein.

BMS has been working with Athersys under a Research Collaboration and License Agreement since July 1, 2002 to create
cell lines that express desired proteins through Random Activation of Gene Expression (RAGE) technology. This original
collaboration was extended by way of the Extended Agreement.

The Parties wish to amend and clarify the Extended Agreement as set forth in this Letter Amendment. All capitalized
terms not defined in this Letter Agreement shall have the meaning given such term(s) in the Extended Agreement.

In order to fulfill its obligations under the Extended Collaboration, whereby BMS was to propose a minimum of three (3)
RAGE-VT cell lines per year over a three year period ending December 31, 2008, both parties agree to extend the period
for cell line proposals, as described in Article 2 of the Extended Agreement, an additional year until December 31,
2009. Further, during 2009 in accordance with its obligations under Article 2, BMS will have the responsibility of
proposing three (3) RAGE-VT cell lines to Athersys, which could include Counterscreening Cell Lines, with the
understanding that BMS will propose at least two (2) RAGE-VT cell lines to Athersys for its review prior to April 30,
2009. A cell line proposed by BMS will be deemed to have been accepted by Athersys upon target approval by Athersys
and receipt by Athersys of payment of Sixty Thousand Dollars ($60,000) from BMS

1

 

5

 

Upon fulfillment of BMS’s above mentioned obligation, Athersys and BMS recognize that BMS shall have fulfilled its
obligations to nominate Collaboration Cell Lines under the Extended Agreement. Further, Athersys warrants and
represents that, to the extent the personnel, capabilities, technologies and intellectual property rights necessary to
make and provide RAGE-VT cell lines are retained by Athersys and available, it will make reasonable efforts to allow
BMS to make use of Athersys’s continued services outlined in the Extended Agreement (i.e. the provision of RAGE-VT cell
lines) on an as needed basis and without an annual minimum cell line requirement; provided, that Athersys has no
obligation to retain personnel, capabilities, technologies and intellectual property for this purpose. For any new
cell lines so proposed by BMS prior to December 31, 2011, the prices, milestones, terms, deliverables and any other
relevant terms in the Extended Agreement shall apply to such cell lines and the services provided to BMS by Athersys.
In the event that Athersys does not have the personnel or operational capabilities to make and provide RAGE-VT cell
lines to BMS, it will make reasonable efforts to provide BMS with materials, instructions, and a limited license to
enable BMS to produce RAGE-VT cell lines on its own, on financial terms to be agreed upon in good faith by the Parties.

This Letter Amendment shall not amend or modify the covenants, terms, conditions, rights and obligations of the Parties
under the Extended Agreement, except as specifically set forth herein. The Extended Agreement shall continue in full
force and effect in accordance with its terms as amended by this Letter Amendment.

This Letter Amendment may be executed simultaneously in two or more counterparts, any one of which need not contain the
signature of more than one Party, but all such counterparts taken together shall constitute one and the same
instrument, and may be executed and delivered through the use of facsimiles or email of pdf copies of the executed
Letter Amendment.

* * * signature page follows * * *

2

 

6

 

IN WITNESS WHEREOF, the Parties, intending to be legally bound hereby, have caused their duly authorized
representatives to execute this Amendment.

Sincerely,

BRISTOL-MYERS SQUIBB COMPANY

/s/ Peter Kramer, Ph.D.

Peter Kramer, Ph.D.

Senior Director, External Science & Technology

Accepted and Agreed by ABT HOLDING COMPANY:

By: /s/ John Harrington            April 7, 2009

Name: John Harrington

Title: Chief Scientific Officer

3

 

7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00157-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00157-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00157-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00157-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00157-of-00352.parquet"}]]